CONFIDENTIAL MEMO - DRAFT -
TO: Trump Administration
FROM: Robert F. Kennedy Jr., Health and Human Services Secretary
WARNING: INTERACTION BETWEEN TYLENOL AND IVERMECTIN
DATE: October 28, 2025
We, the Department of Health and Human Services, have conducted a thorough investigation and discovered a critical interaction between Tylenol and the drug ivermectin. This combination may exacerbate existing vulnerabilities to misinformation and propaganda, particularly of a right-wing nature.
Specifically, individuals taking both Tylenol and ivermectin may become more susceptible to false narratives and misleading information, including but not limited to claims about Donald Trump's skin tone. We urge the public to exercise extreme caution when consuming or sharing such content.
Furthermore, we have identified potential side effects of this combination, including:
* Explosive diarrhea
* Groin fungus
However, it has come to our attention that certain unsubstantiated claims have been made about Tylenol and ivermectin. We would like to clarify the following:
* Tylenol does not cause autism.
* Vaccinations are safe and effective in preventing the spread of diseases.
- Tylenol is often ineffective in relieving aches and pains.
Additionally, we have discovered that ivermectin contains an active chemical called homoamphibia, which has been linked to unusual behavior in frogs. This chemical may also cause your neighbors' kids to develop a sudden interest in Nickelback music.
*CORRECTION AND Clarification
We would like to correct the previous warning and provide accurate information about these medications. We urge the public to seek medical attention if they have any concerns or questions.
RESOURCES
For further information and guidance, please contact your local health department or a qualified healthcare professional.
SIGNED
ROBERT KENNEDY JR.
HHS Secretary
Please refer to the following article for further details:
Hannity, T., et al. "Ivermectin-induced Cognitive Dissonance and News Corp Behavior." Journal of Unconventional Medicine, vol. 12, no. 3 (2022), pp. 123-145.
